D
Janux Therapeutics, Inc.
JANX
$25.77
-$1.22-4.52%
D
Sell
5/9/2024Upgraded
Janux Therapeutics, Inc. (JANX) was upgraded to D- from E+ on 5/9/2024 due to a substantial increase in the total return index, solvency index and valuation index. The quick ratio increased from 26.57 to 61.85.
Janux Therapeutics, Inc. (JANX) was upgraded to D- from E+ on 5/9/2024 due to a substantial increase in the total return index, solvency index and valuation index. The quick ratio increased from 26.57 to 61.85.
E
Sell
3/8/2024Downgrade
Janux Therapeutics, Inc. (JANX) was downgraded to E+ from D- on 3/8/2024 due to a decline in the valuation index, growth index and solvency index. Total revenue declined 2.22% from $2.52M to $2.46M, and EBIT declined 2.05% from -$15.81M to -$16.14M.
Janux Therapeutics, Inc. (JANX) was downgraded to E+ from D- on 3/8/2024 due to a decline in the valuation index, growth index and solvency index. Total revenue declined 2.22% from $2.52M to $2.46M, and EBIT declined 2.05% from -$15.81M to -$16.14M.
D
Sell
2/6/2024Upgraded
Janux Therapeutics, Inc. (JANX) was upgraded to D- from E+ on 2/6/2024 due to an increase in the volatility index, total return index and valuation index.
Janux Therapeutics, Inc. (JANX) was upgraded to D- from E+ on 2/6/2024 due to an increase in the volatility index, total return index and valuation index.
E
Sell
1/22/2024Downgrade
Janux Therapeutics, Inc. (JANX) was downgraded to E+ from D- on 1/22/2024 due to a decline in the volatility index.
Janux Therapeutics, Inc. (JANX) was downgraded to E+ from D- on 1/22/2024 due to a decline in the volatility index.
D
Sell
1/4/2024Upgraded
Janux Therapeutics, Inc. (JANX) was upgraded to D- from E+ on 1/4/2024 due to an increase in the volatility index and total return index.
Janux Therapeutics, Inc. (JANX) was upgraded to D- from E+ on 1/4/2024 due to an increase in the volatility index and total return index.
E
Sell
12/13/2023Downgrade
Janux Therapeutics, Inc. (JANX) was downgraded to E+ from D- on 12/13/2023 due to a decline in the volatility index and total return index.
Janux Therapeutics, Inc. (JANX) was downgraded to E+ from D- on 12/13/2023 due to a decline in the volatility index and total return index.
D
Sell
11/24/2023Upgraded
Janux Therapeutics, Inc. (JANX) was upgraded to D- from E+ on 11/24/2023 due to an increase in the volatility index.
Janux Therapeutics, Inc. (JANX) was upgraded to D- from E+ on 11/24/2023 due to an increase in the volatility index.
E
Sell
11/9/2023Downgrade
Janux Therapeutics, Inc. (JANX) was downgraded to E+ from D- on 11/9/2023 due to a decline in the volatility index and total return index.
Janux Therapeutics, Inc. (JANX) was downgraded to E+ from D- on 11/9/2023 due to a decline in the volatility index and total return index.
D
Sell
10/27/2023Upgraded
Janux Therapeutics, Inc. (JANX) was upgraded to D- from E+ on 10/27/2023 due to an increase in the volatility index and valuation index.
Janux Therapeutics, Inc. (JANX) was upgraded to D- from E+ on 10/27/2023 due to an increase in the volatility index and valuation index.
E
Sell
10/12/2023Downgrade
Janux Therapeutics, Inc. (JANX) was downgraded to E+ from D- on 10/12/2023 due to a decline in the volatility index and total return index.
Janux Therapeutics, Inc. (JANX) was downgraded to E+ from D- on 10/12/2023 due to a decline in the volatility index and total return index.
D
Sell
9/27/2023Upgraded
Janux Therapeutics, Inc. (JANX) was upgraded to D- from E+ on 9/27/2023 due to an increase in the volatility index and valuation index.
Janux Therapeutics, Inc. (JANX) was upgraded to D- from E+ on 9/27/2023 due to an increase in the volatility index and valuation index.
E
Sell
9/12/2023Downgrade
Janux Therapeutics, Inc. (JANX) was downgraded to E+ from D- on 9/12/2023 due to a decline in the volatility index and total return index.
Janux Therapeutics, Inc. (JANX) was downgraded to E+ from D- on 9/12/2023 due to a decline in the volatility index and total return index.
D
Sell
8/24/2023Upgraded
Janux Therapeutics, Inc. (JANX) was upgraded to D- from E+ on 8/24/2023 due to an increase in the volatility index, total return index and valuation index.
Janux Therapeutics, Inc. (JANX) was upgraded to D- from E+ on 8/24/2023 due to an increase in the volatility index, total return index and valuation index.
E
Sell
8/9/2023Downgrade
Janux Therapeutics, Inc. (JANX) was downgraded to E+ from D- on 8/9/2023 due to a decline in the growth index, volatility index and total return index. Total revenue declined 48.39% from $2.05M to $1.06M, operating cash flow declined 8.22% from -$13.91M to -$15.05M, and EBIT declined 2.3% from -$20.28M to -$20.75M.
Janux Therapeutics, Inc. (JANX) was downgraded to E+ from D- on 8/9/2023 due to a decline in the growth index, volatility index and total return index. Total revenue declined 48.39% from $2.05M to $1.06M, operating cash flow declined 8.22% from -$13.91M to -$15.05M, and EBIT declined 2.3% from -$20.28M to -$20.75M.
D
Sell
8/3/2023Upgraded
Janux Therapeutics, Inc. (JANX) was upgraded to D- from E+ on 8/3/2023 due to an increase in the volatility index.
Janux Therapeutics, Inc. (JANX) was upgraded to D- from E+ on 8/3/2023 due to an increase in the volatility index.
E
Sell
7/19/2023Downgrade
Janux Therapeutics, Inc. (JANX) was downgraded to E+ from D- on 7/19/2023 due to a decline in the volatility index and growth index. Total revenue declined 28.01% from $2.85M to $2.05M, operating cash flow declined 16.77% from -$11.91M to -$13.91M, and EBIT declined 11.03% from -$18.27M to -$20.28M.
Janux Therapeutics, Inc. (JANX) was downgraded to E+ from D- on 7/19/2023 due to a decline in the volatility index and growth index. Total revenue declined 28.01% from $2.85M to $2.05M, operating cash flow declined 16.77% from -$11.91M to -$13.91M, and EBIT declined 11.03% from -$18.27M to -$20.28M.
D
Sell
3/14/2023Downgrade
Janux Therapeutics, Inc. (JANX) was downgraded to D- from D on 3/14/2023 due to a decline in the total return index and volatility index.
Janux Therapeutics, Inc. (JANX) was downgraded to D- from D on 3/14/2023 due to a decline in the total return index and volatility index.
D
Sell
2/23/2023Upgraded
Janux Therapeutics, Inc. (JANX) was upgraded to D from D- on 2/23/2023 due to an increase in the valuation index.
Janux Therapeutics, Inc. (JANX) was upgraded to D from D- on 2/23/2023 due to an increase in the valuation index.
D
Sell
2/8/2023Downgrade
Janux Therapeutics, Inc. (JANX) was downgraded to D- from D on 2/8/2023 due to a decline in the solvency index, valuation index and growth index. Operating cash flow declined 120.88% from -$6.07M to -$13.41M, the quick ratio declined from 27.29 to 20.79, and total revenue declined 23.34% from $2.37M to $1.81M.
Janux Therapeutics, Inc. (JANX) was downgraded to D- from D on 2/8/2023 due to a decline in the solvency index, valuation index and growth index. Operating cash flow declined 120.88% from -$6.07M to -$13.41M, the quick ratio declined from 27.29 to 20.79, and total revenue declined 23.34% from $2.37M to $1.81M.
D
Sell
9/6/2022Upgraded
Janux Therapeutics, Inc. (JANX) was upgraded to D from D- on 9/6/2022 due to an increase in the total return index, volatility index and growth index. Total revenue increased 48.84% from $1.59M to $2.37M, and operating cash flow increased 47.29% from -$11.52M to -$6.07M.
Janux Therapeutics, Inc. (JANX) was upgraded to D from D- on 9/6/2022 due to an increase in the total return index, volatility index and growth index. Total revenue increased 48.84% from $1.59M to $2.37M, and operating cash flow increased 47.29% from -$11.52M to -$6.07M.
D
Sell
7/22/2022Downgrade
Janux Therapeutics, Inc. (JANX) was downgraded to D- from D on 7/22/2022 due to a decline in the volatility index, total return index and valuation index.
Janux Therapeutics, Inc. (JANX) was downgraded to D- from D on 7/22/2022 due to a decline in the volatility index, total return index and valuation index.
D
Sell
5/16/2022Upgraded
Janux Therapeutics, Inc. (JANX) was upgraded to D from E+ on 05/16/2022.
Janux Therapeutics, Inc. (JANX) was upgraded to D from E+ on 05/16/2022.
E
Sell
5/13/2022Downgrade
Janux Therapeutics, Inc. (JANX) was downgraded to E+ from D on 5/13/2022 due to a decline in the growth index, valuation index and total return index. Operating cash flow declined 9.93% from -$10.48M to -$11.52M, total revenue declined 1.67% from $1.62M to $1.59M, and EBIT declined 0.39% from -$13.49M to -$13.54M.
Janux Therapeutics, Inc. (JANX) was downgraded to E+ from D on 5/13/2022 due to a decline in the growth index, valuation index and total return index. Operating cash flow declined 9.93% from -$10.48M to -$11.52M, total revenue declined 1.67% from $1.62M to $1.59M, and EBIT declined 0.39% from -$13.49M to -$13.54M.
D
Sell
5/4/2022Upgraded
Janux Therapeutics, Inc. (JANX) was upgraded to D from E+ on 5/4/2022 due to an increase in the volatility index and valuation index.
Janux Therapeutics, Inc. (JANX) was upgraded to D from E+ on 5/4/2022 due to an increase in the volatility index and valuation index.
E
Sell
5/1/2022Downgrade
Janux Therapeutics, Inc. (JANX) was downgraded to E+ from D on 5/1/2022 due to a decline in the volatility index and total return index.
Janux Therapeutics, Inc. (JANX) was downgraded to E+ from D on 5/1/2022 due to a decline in the volatility index and total return index.
D
Sell
4/21/2022Upgraded
Janux Therapeutics, Inc. (JANX) was upgraded to D from E+ on 04/21/2022.
Janux Therapeutics, Inc. (JANX) was upgraded to D from E+ on 04/21/2022.
E
Sell
4/20/2022Downgrade
Janux Therapeutics, Inc. (JANX) was downgraded to E+ from D on 4/20/2022 due to a substantial decline in the efficiency index, total return index and volatility index. Net income declined 24.61% from -$10.77M to -$13.42M, and total capital declined 2.78% from $376.99M to $366.52M.
Janux Therapeutics, Inc. (JANX) was downgraded to E+ from D on 4/20/2022 due to a substantial decline in the efficiency index, total return index and volatility index. Net income declined 24.61% from -$10.77M to -$13.42M, and total capital declined 2.78% from $376.99M to $366.52M.
D
Sell
11/12/2021Downgrade
Janux Therapeutics, Inc. (JANX) was downgraded to D from D+ on 11/12/2021 due to a decline in the total return index and efficiency index. Net income declined 73.48% from -$6.21M to -$10.77M, and total capital declined 2.03% from $384.8M to $376.99M.
Janux Therapeutics, Inc. (JANX) was downgraded to D from D+ on 11/12/2021 due to a decline in the total return index and efficiency index. Net income declined 73.48% from -$6.21M to -$10.77M, and total capital declined 2.03% from $384.8M to $376.99M.
D
Sell
11/3/2021Upgraded
Janux Therapeutics, Inc. (JANX) was upgraded to D+ from D on 11/3/2021 due to a large increase in the solvency index, total return index and valuation index.
Janux Therapeutics, Inc. (JANX) was upgraded to D+ from D on 11/3/2021 due to a large increase in the solvency index, total return index and valuation index.
D
Sell
9/28/2021Downgrade
Janux Therapeutics, Inc. (JANX) was downgraded to D from D+ on 9/28/2021 due to a decline in the total return index and volatility index.
Janux Therapeutics, Inc. (JANX) was downgraded to D from D+ on 9/28/2021 due to a decline in the total return index and volatility index.
D
Sell
9/13/2021Upgraded
Janux Therapeutics, Inc. (JANX) was upgraded to D+ from D on 9/13/2021 due to a large increase in the total return index and valuation index.
Janux Therapeutics, Inc. (JANX) was upgraded to D+ from D on 9/13/2021 due to a large increase in the total return index and valuation index.
D
Sell
9/3/2021None
Janux Therapeutics, Inc. (JANX) was downgraded to D from U on 09/03/2021.
Janux Therapeutics, Inc. (JANX) was downgraded to D from U on 09/03/2021.
NASDAQ
04/04/2025 4:00PM Eastern
Quotes delayed
